132 related articles for article (PubMed ID: 25821156)
1. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
J Clin Pharmacol; 2015 Aug; 55(8):944-52. PubMed ID: 25821156
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
3. Clinical drug interaction profile of idelalisib in healthy subjects.
Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
Ramanathan S; Jin F; Sharma S; Kearney BP
Clin Pharmacokinet; 2016 Jan; 55(1):33-45. PubMed ID: 26242379
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Giri N; Masters JC; Plotka A; Liang Y; Boutros T; Pardo P; O'Connell J; Bello C
Invest New Drugs; 2015 Aug; 33(4):931-41. PubMed ID: 26048096
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
8. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Flinn IW; Kahl BS; Leonard JP; Furman RR; Brown JR; Byrd JC; Wagner-Johnston ND; Coutre SE; Benson DM; Peterman S; Cho Y; Webb HK; Johnson DM; Yu AS; Ulrich RG; Godfrey WR; Miller LL; Spurgeon SE
Blood; 2014 May; 123(22):3406-13. PubMed ID: 24615776
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Abbas R; Chalon S; Leister C; El Gaaloul M; Sonnichsen D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):123-32. PubMed ID: 23053269
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
[TBL] [Abstract][Full Text] [Related]
12. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
13. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
Samant TS; Yang S; Miller M; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1001-1009. PubMed ID: 33555033
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Xin Y; Kawashima J; Weng W; Kwan E; Tarnowski T; Silverman JA
J Clin Pharmacol; 2018 Apr; 58(4):522-532. PubMed ID: 29283448
[TBL] [Abstract][Full Text] [Related]
18. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
19. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
